- Company
- ‘Pluvicto, a new standard therapy for prostate cancer?'
- by Whang, byung-woo Dec 10, 2024 05:52am
- Prostate cancer is one disease area where the treatment environment has been improving with the increasing number of treatment options listed for health reimbursement benefits. Recently, Pluvicto (vipivotide tetraxetan), a radioligand therapy with a new mechanism of action, has emerged and is attracting attention as a viable new standard of c
- Company
- Padcev seeks reimb as mono and combo therapy in KOR
- by Eo, Yun-Ho Dec 9, 2024 05:47am
- The ADC bladder cancer drug Padcev is seeking reimbursement as both monotherapy and combination therapy in Korea. According to industry sources, Astellas Pharma Korea recently submitted reimbursement applications for Padcev (enfortumab vedotin) as monotherapy and combination therapy with PD-1 inhibitor Keytruda (pembrolizumab) in the trea
- Company
- New treatment options for pancreatic cancer arise
- by Son, Hyung Min Dec 9, 2024 05:47am
- New antibody drugs are showing results in pancreatic cancer, a disease area that has been regarded as an incurable disease. Recently, a new bispecific antibody drug from the Dutch company Merus was approved for the treatment of pancreatic cancer in the United States. In clinical trials, the drug has shown therapeutic effects in patients with pan
- Company
- Auto part company confirms potential of novel antibody drug
- by Son, Hyung Min Dec 9, 2024 05:46am
- Kumho HT's candidate product for cancer immunotherapy demonstrated drug tolerance and effectiveness in human-subject clinical trials. At the European Society for Medical Oncology (ESMO) Asia Congress 2024, held for three days from December 6, the Phase 1 clinical trial result of Kumho HT's DNP-002, a new anticancer drug, has been unveiled. Kumho
- Company
- ‘Various treatment options emerged for ulcerative colitis'
- by Son, Hyung Min Dec 6, 2024 05:57am
- “Various treatment options such as biologics and JAK inhibitors have emerged for ulcerative colitis, but the patients’ options are limited because the government does not allow switching between drugs. Especially as the number of young patients in their 20s and 30s and their life expectancy is both increasing, securing various treatment op
- Company
- Roche's new PNH drug 'Piasky' expected to be launched in KOR
- by Eo, Yun-Ho Dec 6, 2024 05:56am
- A new PNH drug, 'Piasky,' is expected to be launched in South Korea. According to industry sources, Roche Korea is currently undergoing the approval review process for Piasky (crovalimab), a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). This drug received the U.S. Food and Drug Administration (FDA) approval in June. In Augus
- Company
- GC Biopharma will distribute and sell Fluad Quad in Korea
- by Kim, Jin-Gu Dec 5, 2024 05:53am
- GC Biopharma will distribute and sell CSL Seqirus’s quadrivalent flu vaccine, ‘Fluad Quad Prefilled Syringe (Fluad Quad),’ in Korea. According to industry sources on the 3rd, GC Biopharma recently signed a contract with Meditip to distribute and sell Fluad Quad in Korea. Meditip holds the domestic rights to the main product of the A
- Company
- Sales of new CAR-T drugs Carvykti 88%↑· Kymriah stalled
- by Son, Hyung Min Dec 5, 2024 05:53am
- Sales performance of Chimeric Antigen Receptor (CAR)-T Cell therapies has been interchanging. Novartis' Kymriah, which entered the market first, is troubling as latecomer competitors enter the market. In contrast, sales of Jansen's Carvykti and BMS' Breyanzi expanded significantly due to expanded indications. According to the pharmaceutical i
- Company
- Biosimilars Onbevezy·Remsima compete for sales lead in KOR
- by Chon, Seung-Hyun Dec 5, 2024 05:53am
- Biosimilars developed by Celltrion and Samsung Bioepis have been expanding their presence in the domestic market. Samsung Bioepis' Onbevezy has surpassed sales of KRW 10 billion, becoming the top-selling biosimilar developed in South Korea. Since Q3 of last year, Celltrion's Remsima has allowed Onbevezy to take a market-leading position. However
- Company
- Boryung starts in-house producing lung cancer drug 'Alimta'
- by Heo, sung-kyu Dec 4, 2024 05:56am
- As Boryung has started in-house production of 'Alimta (pemetrexed),' a non-small cell lung cancer (NSCLC) treatment that Boryung acquired the sales right in 2022, attention is drawn to the background. Analysis indicates that Boryung aims to take a share of the market worth KRW 20 billion as part of a synergistic strategy for operating a manuf
